Arthro Kinetics Share Discussion Threads

[jonwig] 19/5/2006 14:54

Investors Chronicle has a brief, positive, mention:

Arthro Kinetics

Product: Knee and spine regeneration products

Opportunity: Aim-newcomer Arthro Kinetics is the first German healthcare company to float on the junior market. It is developing implants to regenerate joints, using the patient's own cells, and focusing on the knee and spine. The surgery is less invasive and patients recover more quickly, saving healthcare costs, plus the theory is that it need only be done once. Conventional knee and spinal-disc replacements have to be renewed every few years, with more of the knee taken away. The knee cartilage-repair market was worth $500m in 2004, and the spine nucleus-replacement market is expected to be worth $2bn by 2010.

Management/partners: The company is already selling the knee product in Germany, and anticipates US approval in the second half of 2006. Chief executive Robert Guilleume comes from DePuy, owned by Johnson & Johnson, and has 20 years' experience of the hospital market.

Investment verdict: With enough cash to last until break-even (expected in 2007), the shares are good value.

[learntlesson] 18/5/2006 10:22

Hmm and that Mkt Cap is pretty low. Will continue to monitor...

[jonwig] 17/5/2006 16:51

A couple of 'director' (well, senior management) buys reported today.
No great amount, but on a day like this, is pretty unusual.

[jonwig] 22/4/2006 09:35

LL,
I wouldn't worry too much about the warning you flagged up in post #3: it's fairly standard!

I see the dreaded post-IPO droop is catching up with AKI, after it defied gravity for a month or so.

I haven't bought any of these but they certainly look interesting, so I'm monitoring progress.

[learntlesson] 23/3/2006 15:37

Obviously this part not so nice:

History of operating losses and accumulated deficit
The Group has experienced operating losses in each year since its inception and, as at 30 June 2005, the
component companies, EKL and ARS Arthro, had accumulated deficits of approximately £683,182 and
t18,223,000, respectively. The Group expects to incur further substantial operating losses over the next few
years as its research and development and clinical activities continue and increase. There can be no
assurance that the Group will ever achieve significant revenues or profitability.

[learntlesson] 23/3/2006 15:27

Knee Products

CaReS®

CaReS® (Cartilage Regeneration System), is a mechanically stable, homogeneous transplant, consisting of the biological collagen type 1 matrix.

A cartilage biopsy is taken from the patient, and 120ml of autologous blood are collected. A special courier service then delivers the materials to the production facility on the same day. Using an enzymatic process, the chondrocytes are then isolated from the patients cartilage biopsy. The chondrocytes are vital and functional as shown by the synthesis of collagen type 2 and by genetic expression analysis.

In a proprietary process, the freshly isolated chondrocytes are combined with the collagen type 1 matrix. Within minutes of combining the components, the liquid solution becomes a solid gel. The gel is incubated for 9 to 13 days. 11 to 15 days after the biopsy, CaReS® is ready for implantation. However, the Company is currently aiming to reduce the incubation period from 9 to 13 down to 5 to 8 days in order to expedite time to shipment. A special courier service ensures the timely delivery of CaReS® to the hospital for implantation into the patient at a predetermined date.

The size and form of the transplant are easily adaptable intraoperatively. Since the transplant is fixed only with fibrin glue, surgery time and incision length are reduced significantly and rehabilitation can commence earlier. CaReS® is indicated for the repair of articular joint cartilage defects of 2 to 10 cm2 in size. Rehabilitation commences one day after implantation. After a period of 6 to 12 weeks, depending on defect localization, full movement and weight bearing is restored.

Since European approval was granted in October 2002, 700 patients have been treated successfully with CaReS® as at December 2005. Most of these patients were treated for articular knee cartilage defects but five patients were treated for ankle-related cartilage defects.

[learntlesson] 03/3/2006 16:25

RNS Number:1641Z
Arthro Kinetics plc
02 March 2006



Arthro Kinetics plc

First day's dealings in shares of first German healthcare company on AIM

THURSDAY, 2 March 2006 -- Arthro Kinetics plc ("Arthro Kinetics" or "the
Company"), the orthopaedic company dedicated to regenerating joint mobility and
spinal disc function, announces the start today of dealings in its ordinary
shares on AIM under the ticker symbol "AKI".

At the placing price of 120 pence, #6 million before expenses has been raised on
behalf of the Company, including #0.2 million for selling shareholders to meet
tax obligations. This fundraising is in addition to a #2.4 million mezzanine
financing closed in December 2005.

Nomura Code Securities is Nominated Adviser and Broker to the Company.

Bob Guilleaume, Chief Executive Officer, said: "Arthro Kinetics has developed an
exciting range of biologic implants and a suite of surgical instruments which we
believe will set new standards of surgical care, and provide significant
benefits to patients by making knee joint and nucleus disc regeneration a viable
option. We look forward to creating value for shareholders as we implement our
international growth strategy."

[learntlesson] 03/3/2006 16:23

This is the correct thread!
Dedicated to regenerating joint mobility and spinal disc function through the development, manufacture and marketing of advanced biological implants for the regeneration of joint surfaces, and minimally invasive surgical instrument and access systems

Company website:



Company admission prospectus:

[learntlesson] 03/3/2006 16:21

This thread making is a disaster - why dont they let you edit the title!!!

Please go here:

[learntlesson] 03/3/2006 15:59

This thread closed: Please go to

[jonwig] 03/3/2006 15:37

Company website:



Company admission prospectus:



Worth putting into the header?

[jonwig] 03/3/2006 15:33

Thanks LL, very interesting company and product: will keep a watch on this one.

PS - why two threads?Can you put a note on the other one to say it's closed?

[learntlesson] 02/3/2006 09:12

Dedicated to regenerating joint mobility and spinal disc function through the development, manufacture and marketing of advanced biological implants for the regeneration of joint surfaces, and minimally invasive surgical instrument and access systems

Company website:



Company admission prospectus:

[learntlesson] 02/3/2006 08:52

Please go to:

[topvest] 20/10/2004 19:54

Interesting deal today. New web-site for IPOs - its been done before, very unsuccessfully. Maybe ADVFN think that they can leverage off their user base - I will watch with interest anyway!

[michaeld] 02/7/2004 10:42

Yes,we need another 'bubble' of optimism to get things moving again, I reckon. Maybe this Autumn if the doom and gloom about Iraq etc subsides and house prices/interest rates stabilise?

[simonevans] 29/6/2004 20:58

Has anyone else noticed the lack of reverse takeovers on AIM this year? I guess this may be because the direct new issue market is so strong.

[britishbear] 29/6/2004 13:30

Still means your cash is tied up when it could be working for you elsewhere. The longer this goes on the worse I think the result will be. Interesting to see what happens.

[michaeld] 29/6/2004 13:11

Where have you all gone fellow Akaei/Onl fans? Hope I'm not the only one left, to turn out the light?! All we need is a good idea (like an IPO specialist Co? or a reinvented 'Advertwizard') to send this heading in the right direction again; imho. Maybe management are waiting for a period of investment optimism again before a relaunch which is probably a wise decision?